The role of m6A methylation in osteosarcoma biological processes and its potential clinical value

Abstract

Osteosarcoma (OS) is the most common primary malignant bone tumor in children and young adults and has a poor prognosis. Recent developments in the field of high-throughput sequencing technology, particularly in methylated RNA immunoprecipitation sequencing (MeRIP-seq), have led to renewed interest in RNA methylation. Among the various RNA modifications, N6-methyladenosine (m6A) modifications are the most common. Emerging evidence suggests that m6A methylation can affect the complexity of cancer progression by regulating biological functions related to cancer. In this review, we will shed light on recent findings regarding the biological function of m6A methylation in OS and discuss future research directions and potential clinical applications of RNA methyltransferases in OS.

N6-methyladenosine reader YTHDF3 contributes to the aerobic glycolysis of osteosarcoma through stabilizing PGK1 stability

“…Numerous signal pathways mediated by m 6 A are associated with human tumor prognosis. Besides, m 6 A can modulates the expression of transcripts to mediate the target in signalling pathway, leading to methylation change by different m 6 A-correlated enzymes (Wu et al,, 2022). YTHDF3 is a canonical m 6 A reader in the tumorigenesis.…”

“…N 6 -methyladenosine (m 6 A) acts as the most abundant and common mRNA's modi cation, which plays crucial roles and functions in series of biological processes (Dang et al,, 2021, Fang et al,, 2021. The effects of m 6 A on mRNA methylation and its biological functions in osteosarcoma are of great signi cance (Wu et al,, 2022, Zhang et al,, 2021b. For example, m 6 A writer WTAP (Wilms' tumor 1 associated protein) enhanced the stability of FOXD2-AS1 transcripts to promote the methylation modi cation and accelerate the osteosarcoma progression through FOXD2-AS1/m 6 A/FOXM1 complex manner (Ren et al,, 2022).…”

Comprehensive multi-omics analysis reveals m7G-related signature for evaluating prognosis and immunotherapy efficacy in osteosarcoma

“…The specific implications of RNA methylation modifications in osteosarcoma have also been increasingly studied in recent years. Numerous investigations have revealed that methylation modifications extensively regulate osteosarcoma proliferation, apoptosis, migration, invasion, and tumor microenvironment [30] , [31] , [32] . Furthermore, aberrant expression of methylation modification regulators is intimately correlated with poor prognosis and chemotherapy resistance in osteosarcoma [30] , [33] .…”

Identification of key genes and lncRNAs based on M6A methylation regulators and Ferroptosis related genes for the slow flow/no reflow phenomenon

“…However, there is an extreme lack of studies on the correlation between lncRNAs and the slow ow/no re ow phenomenon in STEMI patients, and even fewer studies have discussed the expression of lncRNAs in coronary blood in the presence of slow ow/no re ow, so we believe that lncRNAs and the slow ow/no re ow phenomenon in myocardial ischemia reperfusion injury still need further investigation. N6-methyladenosine (m6A) modi cation is one of the common epigenetic modi cations, accounting for more than 80% of all RNA modi cations [13]. Previous studies have found that m6A methylation is widely involved in the development of various types of cardiovascular diseases [14] and may provide a reference to explore the occurrence of slow ow/no re ow.…”